Skip to main content

Table 2 Log-rank analysis of TTP and OS in the 138 patients who received maintenance therapy

From: Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

Variable Median TTP (months) P value Median OS (months) P value
Age (years)   0.516   0.609
 ≤50 10   42  
 >50 9   36  
Menopausal status   0.306   0.076
 Premenopausal 10   45  
 Postmenopausal 10   37  
KPS score   0.916   0.039a
 70–80 8   33  
 90–100 8   44  
DFS (years)   0.670   0.077
 ≤2 10   34  
 >2 8   43  
No. of metastases   0.081   0.114
 ≤1 14   55  
 >1 9   36  
Site of metastases     
 Viscera 9 0.106 41 0.905
 Non-viscera 13   42  
Response to FCCT   0.883   0.337
 SD 10   41  
 CR + PR 10   43  
  1. TTP time-to-progression, OS overall survival, KPS Karnofsky performance status, CR complete response, PR partial response, SD stable disease, DFS disease-free survival, CT chemotherapy, FCCT first-line capecitabine-based combination chemotherapy
  2. aSince there were only 36 patients in the group whose KPS score was 70-80, no conclusions could be drawn from the log-rank analysis of OS